retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial Retatrutide: The GLP-1/GIP/Glucagon Triple-Agonist Guide to Weight Loss, Appetite Control & Metabolic Reset Efficacy and safety of retatrutide,

Mimic natural GLP-1 hormone better glucose control Slow gastric emptying increased satiety Promote significant weight loss Reduce cardiovascular risks in many patients Key insights: Once-weekly injections improve patient compliance Oral options like Rybelsus are expanding accessibility Dual agonists (like tirzepatide) are pushing outcomes even further But its not just about benefits: Common adverse effects include nausea, vomiting, and GI discomforthighlighting the importance of dose titration and patient monitoring

Consequently, although semaglutide 2.4 mg (Wegovy) had already been approved in 2021 for chronic weight management in adults with obesity or overweight and at least one weight-related condition, the FDA has now expanded this indication to cardiovascular risk reduction in people with concurrent CVD and overweight/obesity

Notably, GLP-1RAs slow the transit time of the gastrointestinal (GI) tract and suppress appetite, which could displace nutrient intake and result in mineral and vitamin deficiencies

[DOI] [PubMed] [Google Scholar] 81.Daniele G., Iozzo P., Molina-Carrion M., Lancaster J., Ciociaro D., Cersosimo E

FIGURE 1 Taken together, these scientific milestones and the rapid rise in scholarly output highlight the momentum of GLP-1based therapies

Additionally, high leptin concentrations may cause oocyte dysfunction (182)